Relationship between impaired BMP signalling and clinical risk factors at early-stage vascular injury in the preterm infant

Motaharehsadat Heydarian,1 Prajakta Oak,1 Xin Zhang,1 Nona Kamgari,1 Alida Kindt,2 Markus Koschlig,1 Tina Pritzke,1 Erika Gonzalez-Rodriguez,1 Kai Förster,1,3 Rory E Morty,4 Friederike Häfner,1 Christoph Hübener,5 Andreas W Flemmer,3 Ali Oender Yildirim,1 Deepti Sudheendra,6 Xuefei Tian,6 Agnese Petrera,7 Holger Kirsten,8 Peter Ahnert,8 Nick Morrell,9 Tushar J Desai,6 Jennifer Sucre,10 Edda Spiekerkoetter,6 Anne Hilgendorff1,11

ABSTRACT

Introduction Chronic lung disease, that is, bronchopulmonary dysplasia (BPD) is the most common complication in preterm infants and develops as a consequence of the misguided formation of the gas-exchange area undergoing prenatal and postnatal injury. Subsequent vascular disease and its progression into pulmonary arterial hypertension critically determines long-term outcome in the BPD infant but lacks identification of early, disease-defining changes.

Methods We link impaired bone morphogenetic protein (BMP) signalling to the earliest onset of vascular pathology in the human preterm lung and delineate the specific effects of the most prevalent prenatal and postnatal clinical risk factors for lung injury mimicking clinically relevant conditions in a multilayered animal model using wild-type and transgenic neonatal mice.

Results We demonstrate (1) the significant reduction in BMP receptor 2 (BMPR2) expression at the onset of vascular pathology in the lung of preterm infants, later mirrored by reduced plasma BMP protein levels in infants with developing BPD, (2) the rapid impairment (and persistent change) of BMPR2 signalling on postnatal exposure to hyperoxia and mechanical ventilation, aggravated by prenatal cigarette smoke in a preclinical mouse model and (3) a link to defective alveolar septation and matrix remodelling through platelet derived growth factor-receptor alpha deficiency. In a treatment approach, we partially reversed vascular pathology by BMPR2-targeted treatment with FK506 in vitro and in vivo.

Conclusion We identified impaired BMP signalling as a hallmark of early vascular disease in the injured neonatal lung while outlining its promising potential as a future biomarker or therapeutic target in this growing, high-risk patient population.

INTRODUCTION

Chronic lung disease (CLD), that is, bronchopulmonary dysplasia (BPD) affects more than 30% of all preterm infants and is characterised by the impaired formation of the gas-exchange area as a result of prenatal and postnatal injury perturbing physiological alveolar and vascular development.1

Following the rarefication of the vascular bed that is tightly intertwined with alveolar simplification2 the development of pulmonary vascular disease (PVD) and the risk for subsequent pulmonary arterial hypertension (PAH) is one of the most severe complications in infants with BPD.3 4 Despite the undeniable clinical significance, earliest, yet disease relevant hallmarks characterising and driving the onset of PVD and later contributing to the progression into PAH, are poorly understood in the BPD context.

KEY MESSAGES

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Bone morphogenetic protein receptor 2 (BMPR2) signalling is a hallmark of pulmonary arterial hypertension.

WHAT THIS STUDY ADDS

⇒ Impaired BMPR2 signalling characterises vascular pathology at its earliest stage in the injured neonatal lung and can thus be considered a potential driver, treatable target and biomarker of disrupted pulmonary development in preterm infants with chronic lung disease, that is, bronchopulmonary dysplasia.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ Our study demonstrates a comprehensive approach including human data and a preclinical, multilayered experimental model meticulously unravelled clinically relevant details of altered BMPR2 signalling in the developing lung undergoing prenatal and postnatal injury, thereby linking vascular pathology during alveolar septation to this critical modulator of pulmonary vessel disease.

Accepted 11 April 2022
Published Online First 17 May 2022

Correspondence to Dr Anne Hilgendorff, Institute for Lung Biology and Disease and Comprehensive Pneumology Center with the CPC/M BioArchive, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Bayern, Germany; Anne.Hilgendorff@mail.uni-muenchen.de

MH, PQ, XZ and NK contributed equally.

In adults and children, critical mechanisms leading to the development of PAH converge on bone morphogenetic protein receptor 2 (BMPR2) signalling with re-establishment of functional BMPR2 signalling representing a key therapeutic goal. Despite the compelling clinical evidence for the significance of the pathway in PVD as well as in organogenesis, the role of BMPR2 in early stage vascular pathology and its relation to the most prevalent clinical risk factors that provoke chronic disease in the preterm lung (CLD) has not been comprehensively explored.

We, therefore, investigated changes in BMPR2 expression in preterm infants with BPD by visualising RNA transcription in the diseased lung, correlating plasma proteomics in BPD infants with structural changes in lung MRI and addressing heritable traits of altered BMP signalling in BPD by the means of a genetic association study in n=1000 preterm infants. We assessed the dynamics of BMPR2 signalling as a developmentally relevant, established driver of vascular disease in response to the most prevalent prenatal and postnatal risk factors for adverse lung development using a multilayered neonatal mouse model. In this model, exposure to clinically relevant levels of mechanical ventilation (MV) and hyperoxia (O₂) as pivotal postnatal risk factors was next combined with the prenatal impact of non-growth restricting doses of cigarette smoke (CS), known to affect one third of all pregnancies. We aimed to anchor BMPR2 signalling in the context of impaired alveolarisation by the use of platelet derived growth factor receptor alpha (PDGF-Rα) deficient mice, thereby addressing the interconnection of both pathways and the link of BMPR2 expression levels to alveolar septation and matrix formation. Finally, we investigated therapeutic strategies using FDA-approved drugs applied in PAH to reverse vascular pathology in the injured neonatal lung in vitro and in vivo.

RESULTS
BMP protein expression as an indicator of early lung vascular injury in preterm infants developing BPD

Physiologically, pulmonary endothelial BMPR2 expression is increased in the developing lung of a preterm when compared with a term infant (figure 1A). In disease, we demonstrated an early decrease in BMPR2 expression in CD31 positive cells in the lung periphery of preterm infants postnatally exposed to MV in comparison to age-matched infants who died in the first hours of life (figure 1B). Partial correlation networks of log-transformed protein expression profiles obtained from proteome analysis (day of life 28; figure 1C) revealed a negative correlation between proteins of the BMPR2 and PDGF signalling cascade and signs of emphysema and interstitial remodelling as obtained by MRI. The network accounted for BPD, days of MV, days of O₂ supplementation and GA (blue line: negative correlation, orange line: positive correlation; octagons: proteins, rectangles: clinical variables; edges significant at false discovery rate (FDR)<0.25). Assessing the impact of hereditary traits on the postnatal impairment in BMPR2 signalling, we performed genetic association analysis for 26 BMPR2-related genes in 1061 preterm infants (n=278 cases with moderate/severe BPD) considering case control status and length of oxygen and/or MV exposure. In 1016 single-nucleotide polymorphisms (SNP) out of 5632 SNPs with nominal significance (p≤0.05), classical BMPR2 polymorphisms known for their relevance in PAH were not associated with the presence of BPD or the duration of MV or oxygen exposure when accounting for multiple testing (online supplemental figure S1). One SNP (rs72917751-C), located in the SMAD7 gene in a genomic region and predicted to be relevant for increased gene transcription in several human tissues including the lung, was associated with the duration of oxygen supplementation (p=1.7×10⁻⁵, FDR=0.48; figure 1D).

Impaired BMP signalling in the developing lung in an early stage of PVD resulting from exposure to the most prevalent risk factors for lung injury in the preterm infant

In our preclinical neonatal mouse model (figure 2A), we showed that O₂ and MV for only 8-hour provoke a significant reduction in pulmonary BMPR2 signalling as reflected by the three-fold reduction in lung protein levels of pSMAD 1-5-9 and its downstream target ID-1 (figure 2B). These changes occur during the earliest stage of lung vascular injury in a critical phase of alveolarisation (postnatal day (PND) 5–8), accompanied by a twofold induction of endothelial cells (EC) apoptosis and a reduction in micro vessel number (20–100 µm diameter; figure 2C). Pulmonary expression of the hypoxia inducible factor (HIF) 1α in these mice remained unchanged (online supplemental figure S2A).

A causal relationship between impaired BMPR2 and EC signalling in the neonatal lung is demonstrated by the use of BMPR2 heterozygote mice, exhibiting decreased baseline levels of lung VE-Cadherin expression and its subsequent reduction on postnatal O₂ exposure (figure 2D). Indicating prolonged effects of MV and O₂ on BMPR2 expression levels, we (1) confirmed the downregulation of BMPR2 expression after extended periods of MV (24 hours) by the use of IHC in vivo (figure 2E) and (2) validated these findings in vitro by imaging RNA expression levels in neonatal mouse precision cut lung slices (PCLS) showing a decrease in BMPR2 transcription in VE-Cadherin positive cells on oxygen exposure for 24-hours (figure 2F). Long-term effects of the early impairment in BMPR2 signalling are demonstrated in 18 months old animals, where lung BMPR2 signalling remained significantly decreased after only 8 hours of moderate postnatal O₂ at PND 3, complyng effects obtained with higher O₂ levels (FiO₂=0.85) (online supplemental figure S2B).

Prenatal exposure to CS resulting in increased pulmonary vulnerability to postnatal injury and aggravated impairment of BMP signalling

In order to assess the additional impact of prenatal lung injury on BMP signalling in the context of early postnatal vascular pathology, we exposed pregnant mice to non-growth-restricting doses of CS, one of the most prevalent prenatal toxins (figure 3A, online supplemental figure S3A). Proving prenatal effects of CS on the developing lung, we demonstrated increased protein levels for pulmonary cytochrome P450 1A1 (CYP1A1) and decreased levels for pulmonary secreted protein acidic and rich in cysteine (SPARC) in the lungs of these neonatal mice (PND 5–8) in comparison to filtered air (FA) controls (online supplemental figure S3B,C). Prenatal CS resulted in increased pulmonary vulnerability towards postnatal lung injury induced by O₂ and MV-O₂ exposure with early-stage vascular injury being tied to a significant reduction in BMP signalling, that is, decreased expression of SMAD 1-5-9 and ID1 as well as BMP4 in total lung homogenates (figure 3B). Pulmonary inflammation as a characteristic sign of lung injury was indicated by accumulation of lung monocytes/macrophages and increased TGF-β signalling following pCS exposure (figure 3C,D). These changes led to increased apoptosis (online supplemental figure S3D) with a twofold increase of VE-Cadherin and cleaved-caspase-3 double positive cells and a subsequent decrease in EC and micro vessel number.

Respiratory research

Figure 1  Decrease in lung vasculature BMPR2 expression and reduced BMP and PDGF plasma levels in preterm infants with BPD in the absence of relevant genetic variants. ISH quantification of BMPR2 and PECAM1+ double positive cells (positive cell area/total cell area; \( \mu \text{m}^2/\mu \text{m}^2 \)) showed (A) the physiological increase in BMPR2 expression per endothelial cell in the developing preterm lung when compared with a term newborn as well as the decrease with mechanical ventilation (MV) in a preterm infant at the same age, that is, 24 weeks gestational age (GA) and (B) a significant reduction of overall pulmonary microvascular BMPR2 expression in the preterm infant undergoing postnatal lung injury induced by the exposure to MV for 2–8 weeks (24–26 weeks GA at birth; n=3/group) when compared with age-matched infants who died in the first days of life. (C) EDTA plasma samples were obtained in preterm neonates GA 25.1–30.6 weeks) with (1) and without (0) BPD at days of life 26–70 and subjected to proteome analysis (Olink proteomics). Infants were characterised for their lung structural changes at term by lung MRI (T2-weighted single-shot fast-spin-echo (ssFSE) sequences; MRI left panel: infant without BPD, MRI right panel: infant with severe BPD in coronal plane showing interstitial enhancement and emphysematous changes. The partial correlation network of log2 transformed protein expression profile obtained by proteome analysis (day of life 28+) reveals a negative correlation between the protein levels of the BMPR2 and PDGF-R\( \alpha \) signalling cascade and the development of emphysema and interstitial remodelling. The network accounts for BPD, days of MV, days of O\( \text{2} \) supplementation and GA (blue line: negative correlation, orange line: positive correlation; octagons: proteins, rectangles: clinical variables). All edges are significant at false discovery rate (FDR)<0.25. (D) Association of rs72917751-SMAD7 with time of supplemented O\( \text{2} \). Rounded gene doses for the rs72917751 genotypes (imputed). association analysis was done using area sinus hyperbolicus transformed values of the time of supplemented oxygen (p=1.7×10^{-5}, FDR=0.48). Association was adjusted for relatedness, gender, gestational age, birth weight <10th percentile, and country of maternal origin. Effect size of rs72917751-SMAD7 in human genetic association analysis. Association of rs72917751 was investigated with BPD case–control status and three measures of respiratory support (area sinus hyperbolicus transformed). Phenotypes were adjusted for relatedness, gender, gestational age, birth weight <10th percentile and country of maternal origin. Data are mean±SD *p<0.01, ****p<0.0001. BMPR2, bone morphogenetic protein receptor 2; BPD, bronchopulmonary dysplasia; ISH, RNA in situ hybridization.
Impaired BMP signalling linked to PDGF-dependent alveolar pathology in the neonatal lung

Linking impaired BMPR2 signalling to the onset of defective alveolar septation, we used transgenic newborn mice to study the impact of deficient PDGF-Rα signalling on BMPR2 function in the neonatal lung undergoing prenatal and postnatal injury (figure 4A). The decrease in PDGF-Rα, a consequence of myofibroblast apoptosis during lung injury, resulted in the enhanced loss of septal quantity associated with structural abnormalities exceeding effects observed in WT littermates (figure 4B–D). These changes were accompanied by the aggravation of EC apoptosis and in the presence of impaired PDGF-Rα signalling, in line with a significant decrease in BMPR2 signalling, that is, ID1 and pSMAD 1-5-9 expression, even exceeding the significant changes provoked by preatal and postnatal environmental hazards in WT littermates (figure 4E–G; online supplemental figure S5).

FK506 treatment restoring impaired BMPR2 signalling in vitro and in vivo

Confirming the in vivo effects, we demonstrated EC-specific effects of O2 and stretch on human primary fetal pulmonary endothelial cells (HPMECs) in vitro (figure 5A): 24 hours exposure of HPMECs to moderate hyperoxia (FiO2=0.4), mechanical stretch or the combination of both results in a significant


Figure 2  Significant reduction in BMP signalling at the earliest stage of lung vascular pathology is accompanied by microvessel loss in postnatal lung injury. (A) Preclinical mouse model of bronchopulmonary dysplasia (BPD) with induction of lung injury by exposure of neonatal mice to mechanical ventilation (MV) and/or hyperoxia (FiO2=0.4) for 8 hours or 24 hours. (B) Immunoblot analysis reveals a significant decrease in pSMAD 1–5–9 and Id-1 protein levels in WT mice in the early course of postnatal lung injury provoked by short-term MV and O2 exposure. (C) Representative images of immunofluorescence (IF) staining for cleaved caspase-3 (green) and VE-cadherin positive cells (red) in lung tissue sections (4 µM, 400X, upper panel; nuclei (DAPI, blue) from 5 to 8 day old pups show a significant increase in EC apoptosis, confirmed by quantitative analysis (lower-left panel). Histological analysis reveals a significant decrease in the number of micro vessels (20–100 µm diameter) in the lungs of mice undergoing only 8 hours of O2 and/or MV when compared with room air (RA) controls (lower-right panel). (D) In BMPR2 deficient mice, immunoblot analysis demonstrates significantly lower VE-cadherin protein expression in the neonatal lung at baseline (RA) when compared with WT pups (left panel). Postnatal exposure to moderate O2 further decreases VE-cadherin protein expression in BMPR2 deficient mice (right panel). (E) Representative images of immunofluorescence (IF) staining for BMPR2 (green) and VE-cadherin positive cells (red) in lung tissue sections (4 µM, 400X, upper panel; nuclei (DAPI, blue) following 24 hours MV show a prolonged and significant decrease in BMPR2 expression, confirmed by quantitative analysis (right panel). (F) ISH demonstrates a persistent decrease in BMPR2 transcription in neonatal mouse PCLS exposed to O2 for 24 hours when compared with RA control samples. Data are mean±SD *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3–4 mice/group compared with RA controls. Quantification of if in 10 fields of view (FOV) per section in two sections per animal, normalisation of positive cells to 100 nuclei; arrows point to positive cells. ISH quantification in 212.55 µm x 212.55 µm FOV. BMP, bone morphogenetic protein; BMPR2, BMP receptor 2; ISH, RNA in situ hybridization; PCLS, precision cut lung slices; VE, vascular endothelial; WT, wild type.
Respiratory research

downregulation of pSMAD 1-5-9 expression (figure 5B). When using mechanical stretch, this effect is enhanced by TGF-β (figure 5C) with maximum effects translating into reduced ID-1 protein levels (figure 5D) together with a decrease in SMAD 4 expression (figure 5E). To evaluate treatment strategies, we subsequently show the potential of FK506 (2 ng/mL) to ameliorate or reverse the effect of stretch and/or O₂ on BMPR2 signalling in HPMECs.

A single dose of FK506 (2 ng/mL) results in increased pSMAD1-5-9 protein levels in HPMECs exposed to O₂ (figure 5F). The effect of FK506 (2 ng/mL) on BMPR2 transcription in HPMECs exposed to O₂ (figure 5G) cannot be observed in human fetal fibroblasts, indicating its cell specificity (online supplemental figure S6A).

A single intraperitoneal dose of 2 ng/mL FK506 increased pulmonary CD31 transcription in vivo (figure 5H; online supplemental figure S6B) and restored VEGF-R2 protein expression (online supplemental figure S6C) in newborn mice in the earliest phase of postnatal injury, that is, exposure to MV-O₂ or O₂ (2 hours). In summary, impaired BMPR2 signalling can be highlighted as a hallmark of early-stage vascular disease in the neonatal lung undergoing prenatal and postnatal injury, aggravated in the context of decreased PDGF-Rα signalling and persisting long term (figure 6).

DISCUSSION

In this study, we demonstrated reduced pulmonary BMPR2 transcription and early postnatal reduction in related plasma protein levels in infants with characteristic lung structural changes. We addressed the...
impact of hereditary traits on early postnatal BMPR2 signalling in a genetic association study, and by the lack of an association suggest a role of secondary, environmental causes for the postnatal reduction in BMPR2 signalling in the preterm infant with evolving PVD.\(^{21}\)

In subsequent experimental studies that allowed us to assess the dynamics of BMPR2 signalling in a multilayered preclinical mouse model, we successfully demonstrated the significant reduction in BMPR2 expression in early PVD caused by both prenatal and postnatal injury. We thereby established impaired BMPR2 signalling, a hallmark of PAH together with early EC apoptosis and microvessel growth restricting doses of CS.\(^{18}\) The mimic of clinically relevant settings significantly added to previous studies using non-physiological injury conditions.\(^{21}\)

As demonstrated in our study, the impairment of BMPR2 signalling occurs at the earliest stage of PVD during the critical window of alveolarisation, indicating its important role in BPD-related vascular pathology as opposed to a mere end-stage phenomenon. The loss of physiologically heightened BMP receptor and ligand expression levels likely results in lasting effects,\(^{25}\) supported by our findings with a lack of compensatory upregulation in BMPR2 signalling after short-term injury as well as its long-term impairment in adult mice following neonatal oxygen exposure. The decrease in BMPR2 signalling can be related to BPD characteristic inflammatory processes\(^{26}\) in addition to the effects of oxygen\(^{25}\) and mechanical shear stress\(^{27,28}\) alone.

In line with previously published data from our group\(^ {19,29}\) differences in response to MV/stretch in combination with O\(_2\) or O\(_2\) alone can be observed in vitro and in vivo, suggesting the activation of both incremental as well as differential mechanisms.

Successfully anchoring impaired BMPR2 signalling in the context of BPD characteristic lung structural changes, we established its interdependency with PDGF-Rx expression, that is, known to hold critical functions in alveolar septation, extracellular matrix formation and vascular development.\(^ {19,20,30,31}\) The intertwined regulation of both pathways supports the relation of lung fibrosis and vascular pathology indicated by previous studies,\(^ {32,33}\) aggravated by the proliferation of apoptosis-resistant ECs in the presence of impaired BMPR2 signalling\(^ {34}\) and the subsequent exposure of subendothelial cells to growth factors and chemokines due to decreased EC barrier function.\(^ {35}\) Uncontrolled fibroblast proliferation likely increases further in the absence of higher-functioning PDGF-Rx positive fibroblast.\(^ {36}\) We recapitulated vascular remodelling showing the enhanced

---

Figure 4  Aggravated loss of BMPR2 signalling and increased vascular pathology in the presence of BPD characteristic PDGF-Rx deficiency. (A) In our preclinical model, PDGF-Rx heterozygote (PDGF-Rx\(^+/-\)) neonatal mice and WT littermates were exposed to pCS and postnatal MV and/or hyperoxia (FiO\(_2\)=0.4) for 8 hours. (B) Exposure to pCS resulted in a significant increase in apoptosis of PDGF-Rx expressing cells (PDGF-Rx and cleaved caspase-3 double positive cells), aggravated by postnatal exposure to O\(_2\) or MV-O\(_2\), (C, D). The reduction in PDGF-Rx expression is accompanied by an increased loss of septal crests and elastic fibres (Hart's stain) on postnatal O\(_2\) exposure (4\(\mu\)M, 400X) in the lungs of 5–8 days old mice. (E) Quantification of if staining in lung tissue sections show enhanced EC apoptosis in PDGF-Rx\(^+/-\) neonatal mice exposed to pCS and maternal O\(_2\), that is, increase in VE-cadherin (red) and cleaved caspase-3 (green) double positive cells (4\(\mu\)M, 400X, left panel; nuclei (DAPI, blue). (F) Subsequently, mRNA analysis demonstrates decreased ID1 mRNA expression in lungs from PDGF-Rx\(^+/-\) mice exposed to short-term postnatal O\(_2\), exceeding the effect in WT littermates achieved by O\(_2\) alone or in combination with pCS. (G) ISH quantification demonstrates the parallel decrease in PDGF-Rx and BMPR2 transcription in WT mice undergoing prenatal and postnatal injury, that is, pCS and MV-O\(_2\). Data are mean±SD. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3-4 mice/group. Quantitative analysis of IF images are performed in 10 fields of view (FOV) per section in a total of 2 sections per animal, normalisation of positive cells to 100 nuclei; arrows point to positive cells. ISH quantification in 212.55 µm x 212.55 µm. BMPR2, bone morphogenetic protein receptor 2; BPD, bronchopulmonary dysplasia; EC, endothelial cell; FA, filtered air; MV, mechanical ventilation; PCS, prenatal cigarette smoke; WT, wild type.
presence of mature elastic fibres in the wall of small lung vessels side-by-side with alveolar simplification and interstitial remodelling after perinatal and postnatal lung injury.19

The observed relation of PDGF-Rα and BMPR2 signalling reflects impaired pathway cross-talk as demonstrated in mesenchymal cells37 with relevance for EC function38 and VEGF-dependent EC survival,2,39 underscoring the close relation of vascular and alveolar pathology.2 Mimicking fibroblast loss through apoptosis, reduced PDGF-Rα expression negatively affects rescue mechanisms of BMP deficiency,40 and BMP secretion by lung fibroblasts.41 Studies demonstrated the decrease of ligand-activated endocytosis of the BMPR2 receptor in the presence of VEGF deficiency, thereby arresting its signalling.42 Taken together with our findings, the lack of compensation for impaired BMPR2 signalling by, for example, HIF2α or (PDGF-Rα dependent38) VEGF-A regulation hinders the restoration of EC signalling and vascular function in the neonatal lung, including abnormal metabolic and mitochondrial cell function.22,26

The potential of BMPR2 as a therapeutic target5,6 is supported by the successful stimulation of BMPR2 signalling by the US Food and Drug Administration (FDA)-approved drug FK506 (Tacrolimus)7 in a BPD-relevant context. In line with studies in adult PAH, FK506 rescued receptor expression and enhanced EC survival in vitro and in vivo during early injury. Although previous studies were unsuccessful to prevent BPD development by nitric oxide (NO) supplementation,43 future studies in BPD should address the potency of prostacyclins, sildenafil, recombinant BMP9 or Elafin.44,45 to restore impaired BMP signalling in the BPD lung while considering the coregulation of BMPR2 signalling with endothelin, NO46 and surfactant production.47

In summary, we established impaired BMPR2 signalling in the early phase of PVD in response to the most prevalent clinical risk factors for lung injury and BPD development in preterm infants, thereby linking a hallmark of PAH with significant diagnostic and therapeutic potential to this high-risk patient cohort. The powerful combination of the most prevalent and relevant prenatal and postnatal risk factors for neonatal lung injury in a unique, multilayered preclinical animal model using wild-type and transgenic mice, enabled us to demonstrate both the dynamics as well as the clinical significance of reduced BMPR2 signalling hand-in-hand with the impaired expression of the respective signalling molecules in the circulation of the preterm infant with BPD. Aggravation of the BMP phenotype in the presence of impaired PDGF signalling points towards an important interaction of the pathways in BPD while reflecting on the interconnection of fibrosis development and vascular pathology. Testing the potential of the therapeutic stimulation of BMPR2 signalling in the injured neonatal lung, our study indicated the clinical potential of the BMP pathway as an indicator and therapeutic target of PVD in BPD.

Limitations of the study are the number of infants recruited for the translational studies, although we deem the number reasonable given the background of extreme prematurity. The lack of functional immaturity in the newborn mouse lung in comparison to the preterm infant requires additional preclinical studies to develop sufficient treatment options.

Following up on the results obtained by us, treatment strategies for preterm infant should be assessed for their potential to enhance BMP signalling, especially when aiming to improve vascular function and reduce risk for PVD. Future studies need to furthermore address the effect of reduced BMPR2 signalling in different cellular
compartments of the neonatal lung, thereby providing insight into the interconnection of pathways in PVD and PAH development.

MATERIALS AND METHODS

Human studies

Human lung tissue analysis

Human lung tissue from autopsy specimens (EC #6 (Vanderbilt University) of preterm infants (23–26 weeks GA) that died within the first hours after birth or in the first week of life after MV and supplemental O2, respectively. Lung tissue from a term infant that died from a non-pulmonary cause served as a reference. sRNA in situ hybridisation by RNA scope (ACDBio) for BMPR2, PECAM1 (human), positive (Ppib) and negative (DapB) control was performed according to the manufacturer’s instructions. Automated analysis by Halo software (Indica Labs) from fluorescent images used Keyence BZ-X710, BZ-X Viewer software (405, 488, 561, 647 nm; 400x). Comparative analysis was performed in two different ways: In figure 1A, each data point represents the result obtained for an individual cell quantifying the area of BMPR2 over total cell area (10 FOV/slide; 4 slides/infant). In figure 1B, each data point represents the overall % positive BMPR2 cells in the lung periphery quantified in 10 FOV/slide, 4 slides/infant.

Proteomic analysis in preterm plasma samples

Twenty-eight preterm infants <32 weeks GA with and without later development of BPD were included in the study (perinatal centre, LMU Hospital; EC #195-07). Plasma was derived from EDTA blood specimens at day of life 26–70. For patient characteristics, see online supplemental table S1. The infants have been characterised for lung structural changes (emphysema and interstitial remodelling) as assessed by MRI near term, that is, 36 weeks GA (3 Tesla MRI) using a 5-point Likert scale.

All samples (n=28) were randomised including inter-plate controls and measured by proximity extension assay (Olink Proteomics, Uppsala, Sweden: cardiometabolic (V3602), cardiovascular II (V5004), development (V3511), inflammation (V3012), metabolism (V3402), neurology (V8011), oncology II (V7002)) following the manufacturer’s instructions followed by quantification (Fluidigm BioMark HD Real-Time PCR). NPX values were intensity normalised (plate median for each assay as normalisation factor (Intensity Normalisation V.2); samples or proteins failing quality control were excluded. Partial correlation networks were calculated using R (V4.0.0, package GeneNet (V1.2.15) with the ggm::pcor function after missing values were imputed using the imputeKNN method.)

Figure 6  Graphical abstract. Impaired BMPR2 signalling as a hallmark of early-stage vascular disease in the neonatal lung undergoing prenatal and postnatal injury, aggravated in the context of decreased PDGF-Rα signalling and persisting long term. We demonstrate that the exposure of the preterm lung to postnatal injury provokes an early and significant decrease in endothelial BMPR2 expression, mirrored by the joined reduction of BMP and PDGF plasma protein levels in preterm infants with a developing chronic pulmonary condition. Using multilayered preclinical models, we delineate the specific effects of the most prevalent prenatal and postnatal clinical risk factors and show early endothelial cell apoptosis and microvessel loss tied to a significant decrease in BMP signalling. The changes in BMP signalling persist long-term, are causally related to impaired PDGF-Rα expression driving septation defects and can be targeted therapeutically using an FDA approved drug. In part, the schematic was created using Servier medical art templates, creative commons Attribution V.3.0 Unported license; https://smart.servier.com. BMP, bronchopulmonary dysplasia; BMPR2; BMP receptor 2; CLD, chronic lung disease; FA, filtered air; FDA, US Food and Drug Administration; MV, mechanical ventilation; pCS, prenatal cigarette smoke.
Pulmonary MRI
Preterm infants underwent 3T MRI in spontaneous sleep at 36 weeks GA. T2-weighted single-shot fast-spin-echo sequences were quantified by a consensus panel of two senior neonatologists and two senior radiologists, blinded to the clinical diagnosis using defined criteria for scoring the presence of emphysema and interstitial enhancement on a 5-point Likert scale in four quadrants using coronal, axial, and sagittal images.

Genetic association study
DNA extraction, genotyping and association analysis were performed as previously described. Briefly, DNA was extracted from EDTA cord blood samples of n=1061 preterm infants (n=278 moderate/severe BPD) ≤ 32 weeks GA. Clinical characteristics including days of invasive and non-invasive ventilation and O2 were available for n=982 and 1029 infants and area sinus hyperbolicus transformed. Genotypes of patients were determined using Affymetrix Axiom microarrays (Axiom CEU array with custom content), imputation of the data used 1000 Genomes phase 1, V3 as reference panel (genome built hg19/dbSNP 135). Association analysis of SNPs and case-control status as well as with history of respiratory support was adjusted for relatedness as previously described and accounted for gender, GA, birth weight <10th percentile and country of maternal origin. The role of genetic variants in the BMPR2 pathway used a total of 5632 SNPs (data.frame x5, MAF filtering) with minor allele frequency ≥1% and imputed info score ≥0.5 in or near (±5 kb) the genes ACVR1, ACVR2A, ACVR2B, ACVR1L, BMP 2, BMP 4, BMP 6, BMP 7, BMPR1A, BMPR2, CAV1, Endoglin, FKBP1A, GDF2, ID1, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD7, SMAD9, TGFBI, TGFBR2, TGFBR1 and TGFBR2. Correction for multiple testing was done using FDR (Benjamini and Hochberg).

Animal studies
Animal maintenance
For breeding, pathogen-free male and female C57BL/6 (wild-type, WT) and transgenic mice were obtained from Charles River Animal Care and Use Committee.

Gene-targeted mice
PDGF-Rα haploinsufficient mice (B6.129S4-Pdgfra tm11(EKFP)Woe), no reported lung abnormalities) from Jackson laboratories (Bar Harbour, USA) were bred using homozygous male and WT female mice to avoid effects of maternal PDGF-Rα heterozygosity. BMPR2 heterozygous mice (BMPR2 -/; C57BL/6 background) were provided from Dr. Rabinovich’s Laboratory (Stanford University). Transgenic mice were compared with WT littermates.

pCS exposure
Pregnant female mice were exposed to whole-body active 100% mainstream total particulate matter (3R4F low tar modern research cigarettes (Tobacco Research Institute, University of Kentucky, USA), 500 mg/m³, 30 min, twice/day) from day 7 to 18 of gestation (total 10 days CS) using an exposure chamber via a membrane pump.

MV and O2 experiments in neonatal mice
We randomly assigned term born 5–8-day-old male and female WT and transgenic mice (WT 3.7±0.5 g; body weight (bw), PDGF-Rα+/- 3.7±0.6 g; mean±SD) into three groups (13–16 mice per group), that is, 8h of MV with O2 (MV-O2, FiO2 0.4), O2 only (FiO2=0.4) and room air controls (FiO2=0.21). As published previously, mice underwent (1) tracheotomy after ketamine (∼60 µg/g bw) and xylazine (∼12 µg/g bw) sedation for MV-O2 at 180 breaths/min (MicroVent 848; Harvard Apparatus, Holliston, MA; mimic of clinical conditions; mean tidal volume 8.68 mL/bw; peak airway pressure 12–13 cmH2O, mean airway pressure 11–12 cmH2O) or (2) spontaneously breathed O2 or RA after sham surgery under mild sedation. Viable pups were euthanised (sodium pentobarbital) and lungs were harvested for analysis. For analysis of long-term effects, 5–8-day-old male and female WT mice were exposed to O2 or RA with the mothers, kept alive, weaned using a standard procedure and sacrificed at 18 months of age. Sixteen 5–8-day-old WT newborn mice (3.7±0.5 g bw, mean±SD) received 2 ng/mL FK506 in 100 µL/g bw 0.9% sterile saline intraperitoneally or sterile saline only before the onset of MV-O2.

Postmortem processing of lungs for quantitative histology
Lungs for histology from randomly selected mice (n=3/group) were fixed intratracheally with buffered 4%-PFA overnight at 20 cmH2O. After paraffin-embedding and isotropic uniform random sectioning relative amount and distribution of insoluble lung elastin were obtained from Hart’s elastin stain as previously described. Representative pictures (3/animal) were obtained at 40x to assess alveolar and vascular structure.

Immunohistochemistry
Sections from 3 to 6 animals/group were incubated with peroxidase blocking reagent (Sigma, #13642), normal goat serum, primary antibodies (rat anti-F4/80: 1:400 ab66460 (Abcam)) and biotinylated goat anti-rat secondary antibody (1:200, Santa Cruz Biotechnology). Visualisation with streptavidin-HRP and diaminobenzidine (Dako, North America) was completed by counterstaining (haematoxylin (Richard-Allan Scientific, Kalanazzo, MI) and mounting (Dako, North America, #53023). Positively stained cells were quantified in 20 F0V/slide (400X magnification).

Immunofluorescence
Sections from (2–6 animals/group) underwent antigen retrieval (0.1 M citric buffer, pH 6.2-6.9°C), tissue permeabilisation (Triton X-100 (0.5%)), 20' and H2O2 treatment followed by antibody incubation (4°C overnight; PDGF-Rα (C-20, Santa Cruz Biotechnology #3338), VE-Cadherin (H-72, Santa Cruz Biotechnology, #28644), cleaved caspase-3 (Cell Signalling Technology, #9661). Detection with Alexa 488/568 labelled goat anti-mouse antibody (Molecular Probes; Eugene, OR; 60') was complemented by DAPI counterstain (Sigma Aldrich #D8417). Total nuclei and single/double positive cells were quantified in 8 FOV/slide per animal (n=2–6 mice/group) (400x; IMARIS Software, Zurich, Switzerland).

Quantitative real-time RT-PCR
Total RNA from lung tissue homogenate was isolated using the peqlab-Gold Total RNA-Kit (Peqlab, Erlangen, Germany, #12-6834-01) before cDNA synthesis (random hexamers, MuLV reverse transcriptase (Applied Biosystems, Germany)). mRNA expression of target and housekeeping gene (hypoxianine-guanine phosphoribosyltransferase, HPRT-1) expression was determined by Platinum SYBR Green qPCR SuperMix (Applied Biosystems; StepOnePlus 96 well RTPCR System (Applied Biosystems, CA) and displayed as 2-ΔΔCT (ΔΔCT = ΔCTtarget - ΔCTreference) or as 2-ΔΔCT values (∆∆CT = ∆CTtarget - ∆CTreference).
Protein extraction and immunoblot analysis

Protein was extracted from snap-frozen total lungs using high urea buffer (KPO4, Urea, AppliChem) with halt protease inhibitor (Thermo Fisher Scientific, #1861280); protein concentration measurement used BCA, Pierce Scientific Rockford, USA, #23227. Immunoblotting on Bis-Tris or Tris-Acetate gels (Life Technologies, Germany, #NP0321BOX, #EA0375BOX) included detection of CYP1A1 (A-9, Santa Cruz Biotechnology #SC-393979), ID1 (Abcam #ab168256), SMAD2/3 (Cell Signalling Technologies #3102), pSmAD2 (Cell Signalling Technologies #3101), SMAD1 (Cell Signalling Technology, #6944), pSmAD1-5-9 (Cell Signalling Technology, #9511), SMAD4 (Santa Cruz Biotechnology, #7966), SPARC (D10F10, Cell Signalling Technologies #8725), VE-Cadherin (H-72, Santa Cruz Biotechnology #28644), VEGF-A (147, Santa Cruz Biotechnology #507), VEGF-R2 (R and D system, #AF644) and β-actin (Santa Cruz Biotechnology, #sc-81178) (secondary antibodies goat anti-rabbit IgG (Santa Cruz Biotechnology, #2001) or goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, #sc-81178)). Image quantification used chemiluminescence (ChemDoc XRS+; GE Healthcare, Buckinghamshire, UK #RPN2232) and densitometry (Image Lab Software, Bio Rad, Munich, Germany).

In vitro experiments

Human pulmonary microvascular endothelial cells (HPMECs)

HPMECs (ScienCell Research Laboratories, CA, #3000) were cultured in ECM (ScienCell Research Laboratories, #1001) in 75 mL falcon flasks to 80%-90% confluency and seeded on flexible-bottomed laminin-coated 6 well plates (FlexCell International Corporation, #BF-3001L) for stretching experiments with 24 hours resting before experiments.

In vitro stretch

Cultured HPMEC’s underwent cyclic stretch by vacuum pressure (shape/sine; elongation min 0%, max 8%; frequency 2 Hz; duty cycle 50%; cycles 43216) for 24 hours before incubation with TGF-β (5 ng/mL) and/or FK506 (2 ng/mL).

In vitro hyperoxia

Cultured HPMEC’s underwent hyperoxia (FiO2=0.4, 5% CO2, 95% humidity, 37°C) or normoxia (FiO2 =0.21) for 24 hours before incubation with TGF-β (5 ng/mL) and/or FK506 (2 ng/mL).

Immunoblot analysis

After cell lysis with RIPA buffer and halt protease inhibitor cocktail (Thermo Fisher Scientific, #1860932), determination of protein concentration and immunoblot analysis followed the above protocol.

Precision cut lung slices

The 300μm PCLS from 4 to 7-day-old mice were cultured in DMEM-F12 for 24 hours in O2 (FiO2 =0.7) or RA (FiO2 =0.21) (5% CO2, 37°C) before formalin fixation, paraffin embedding and sectioning.63

RNA scope

RNA in situ hybridisation was performed as described above using Vim, Pdgfra, BMPR2 (mouse), positive (Pipib) and negative (DapB) control (ACDBio).

Statistical analysis

Statistical analysis was performed using the Prism V8 software package (GraphPad, San Diego, California, USA). Multiple testing used two-way analysis of variance with Bonferroni correction; comparisons of two groups/parameters used student’s unpaired t-test with Welch’s correction. Results are given as mean and SD, numbers of each experiment are presented in the figures legend.

Analysis of proteomic and genetic association data is described above in the respective method’s section.

Author affiliations

1Institute for Lung Biology and Disease and Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
2Division of Analytical Biosciences, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands
3Department of Neonatology, D: v. Hauner Children’s Hospital, Ludwig-Maximilians University, LMU Hospital, Munich, Germany
4Department of Translational Pulmonology, University Hospital Heidelberg, Translational Lung Research Center campus of the German Center for Lung Research (DZL), Heidelberg, Germany
5Department of Obstetrics and Gynecology, Ludwig-Maximilians University, LMU Hospital, Munich, Germany
6Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, California, USA
7Research Unit Protein Science and Metabolomics and Proteomics Core, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
8Institute for Medical Informatics, Statistics, and Epidemiology (IMISE), associated partner of the German Center for Lung Research (DZL), University of Leipzig, Leipzig, Germany
9Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
11Mildred Stahmann Division of Neonatology, Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, USA
10Center for Comprehensive Developmental Care (CDeCLMU), Ludwig-Maximilians University, LMU Hospital, Munich, Germany

Twitter Ali Oender Yildirim @AliOnderCPC

Acknowledgements We sincerely thank the patients and their families of the AIRR study cohort for their significant contribution to the study by providing the samples.

Contributors Conception and design of the manuscript was done by AH and ES. The data were acquired by PO, MH, NK, XZ, EG-R, JS, AP, MK, AWE, CH, DS, XT, AYO, TP. The data analysis and interpretation were done by AH, PO, MH, KF, JS, NM, AK, TP, PA, HK and REM. The manuscript was written by MH and AH. The manuscript was drafted for important intellectual content by AH, ES, JS, TJD. AH has full access to all the data in the study and takes the responsibility for the integrity of the data and the accuracy of the data analysis.

Funding The present study was supported by the Young Investigator Grant NWG VH-NG-829 by the Helmholtz Foundation and the Helmholtz Zentrum Muenchen, Germany, the International Research Group ‘Role of BMP signalling’ (01KJ07110), Helmholtz Foundation (German Ministry of Education and Health (BMBF)) and the German Centre for Lung Research (DZL, German Ministry of Education and Health (BMBF)) as well as as well as the Research Training Group Targetes in Toxicology (GRK2338) of the German Science and Research Organisation (DFG) and the Progress Study Group (BMBF Grant 01KJ0101C, BMBF Grant 01K10101).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by human lung tissue analysis: Vanderbilt University Institutional Review BoardProteomic analysis in preterm plasma samples: Ethics committees the Ludwig Maximilian-University (Ethics approval #195-07).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which


Copyright 2022 BMJ Publishing Group. All rights reserved. For permission to reuse this article in print or electronic format, please contact permissions@bmj.com.
permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORBID IDs
Motaharesa Sadat Heydarian http://orcid.org/0000-0003-4411-5371
Kai Förster http://orcid.org/0000-0002-4127-1400
Ali Gender Yildirim http://orcid.org/0000-0003-1969-480X

REFERENCES
Supplementary

Fig S1

A) Reset to query variant

B) Active TSS

Strong transcription

Enhancers

<table>
<thead>
<tr>
<th>Chroatin state</th>
<th>Chromatin state window</th>
<th>Organ</th>
<th>Dataset</th>
</tr>
</thead>
<tbody>
<tr>
<td>chr18:46449600..46449800</td>
<td>lung</td>
<td>ENCSR880GEJ</td>
<td></td>
</tr>
<tr>
<td>chr18:46449000..46450400</td>
<td>lung</td>
<td>ENCSR581XSG</td>
<td></td>
</tr>
<tr>
<td>chr18:46449400..46449800</td>
<td>lung</td>
<td>ENCSR121XQI</td>
<td></td>
</tr>
<tr>
<td>chr18:46449600..46450200</td>
<td>Connective tissue, lung</td>
<td>ENCSR930HTG</td>
<td></td>
</tr>
<tr>
<td>chr18:46448000..46450200</td>
<td>lung</td>
<td>ENCSR097DGY</td>
<td></td>
</tr>
</tbody>
</table>
Fig S2

A

HIF1A mRNA

HPRT mRNA

FA/RA

FA/MV-O₂

B

ID1

β-actin

21% O₂

40% O₂

85% O₂

16 kDa

43 kDa

ID1 Protein

β-actin Protein

21% O₂

40% O₂

85% O₂

*
Fig S3

A

Body Weight (g)

<table>
<thead>
<tr>
<th></th>
<th>FA</th>
<th>pCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>RA</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

B

CYP1A1 Protein

<table>
<thead>
<tr>
<th></th>
<th>FA RA</th>
<th>pCS RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>2.0</td>
<td>1.5</td>
</tr>
<tr>
<td>RA</td>
<td>2.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

β-actin Protein

<table>
<thead>
<tr>
<th></th>
<th>FA RA</th>
<th>pCS RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>RA</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

C

SPARK Protein

<table>
<thead>
<tr>
<th></th>
<th>FA RA</th>
<th>pCS RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>4.0</td>
<td>3.5</td>
</tr>
<tr>
<td>RA</td>
<td>2.0</td>
<td>3.0</td>
</tr>
</tbody>
</table>

β-actin Protein

<table>
<thead>
<tr>
<th></th>
<th>FA RA</th>
<th>pCS RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>RA</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

D

Cleaved Caspase-3

FA MV-O2

pCS MV-O2

E

VE-Cadherin Protein

<table>
<thead>
<tr>
<th></th>
<th>FA RA</th>
<th>pCS RA</th>
<th>FA MV-O2</th>
<th>pCS MV-O2</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>1.0</td>
<td>1.0</td>
<td>2.0</td>
<td>2.5</td>
</tr>
<tr>
<td>RA</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

β-actin Protein

<table>
<thead>
<tr>
<th></th>
<th>FA RA</th>
<th>pCS RA</th>
<th>FA MV-O2</th>
<th>pCS MV-O2</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>RA</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

## References

Fig S5
Fig S6

A

B

human fetal lung fibroblasts

O₂
O₂
FK(2ng/ml)

CD31 mRNA
HPRT mRNA

RA
PBS
RA
FK
(2ng/ml)

C

VEGF-R2
β-actin

MV-O₂+
PBS
MV-O₂+
FK(2ng/ml)

VEGF-R2
β-actin Protein

MV-O₂+
PBS
MV-O₂+
FK(2ng/ml)
Table S1. Patient characteristics preterm infants.

Data are given as median and range or number and percent of total in group respective range.
GA, gestational age; IUGR, intrauterine growth retardation; ANCS, antenatal corticosteroids; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage; ICU, intensive care unit; BPD, bronchopulmonary dysplasia. NA (not available): IUGR n=3; PDA n=7. Intrauterine growth restriction was defined as birth weight below the 10th percentile. Postnatally, diagnosis and severity of respiratory distress syndrome (RDS) were scored on anterior-posterior (a.-p.) chest radiographs according to Couchard et al (1). Chorioamnionitis was defined as inflammatory alterations of the chorionic plate (histologic examination) or signs of maternal and fetal signs of infection (2) Systemic infections were diagnosed according to Sherman et al. (3) based on one or more clinical and laboratory signs of infection. BPD was defined according to Jobe and Bancalari (4) and graded as mild (oxygen supplementation at 28 days postnatally), moderate (oxygen supplementation < 30% and/or ventilator support at 36 weeks postmenstrual age), and severe (oxygen supplementation > 30% and/or ventilator support at 36 weeks postmenstrual age).


<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>GA (weeks)</td>
<td>28.2</td>
<td>(25.1-30.6)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>1031</td>
<td>(650-1770)</td>
</tr>
<tr>
<td>IUGR</td>
<td>2</td>
<td>(8%)</td>
</tr>
<tr>
<td>Gender (female/male)</td>
<td>12/16</td>
<td></td>
</tr>
<tr>
<td>ANCS</td>
<td>25</td>
<td>(89.3%)</td>
</tr>
<tr>
<td>Chorioamnionitis</td>
<td>11</td>
<td>(39.3%)</td>
</tr>
<tr>
<td>Early onset infection</td>
<td>7</td>
<td>(25.0%)</td>
</tr>
<tr>
<td>RDS≥II*</td>
<td>7</td>
<td>(25.0%)</td>
</tr>
<tr>
<td>Days of mechanical ventilation</td>
<td>34</td>
<td>(0-70)</td>
</tr>
<tr>
<td>Days of oxygen supplementation</td>
<td>22</td>
<td>(0-88)</td>
</tr>
<tr>
<td>PDA</td>
<td>18</td>
<td>(78.3%)</td>
</tr>
<tr>
<td>Postnatal steroids</td>
<td>10</td>
<td>(35.7%)</td>
</tr>
<tr>
<td>ROP</td>
<td>5</td>
<td>(17.9%)</td>
</tr>
<tr>
<td>IVH</td>
<td>2</td>
<td>(7.1%)</td>
</tr>
<tr>
<td>ICU days</td>
<td>64</td>
<td>(30-109)</td>
</tr>
<tr>
<td>BPD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- None</td>
<td>17</td>
<td>(60.7%)</td>
</tr>
<tr>
<td>- Mild</td>
<td>7</td>
<td>(25.0%)</td>
</tr>
<tr>
<td>- Moderate</td>
<td>3</td>
<td>(10.7%)</td>
</tr>
<tr>
<td>- Severe</td>
<td>1</td>
<td>(3.6%)</td>
</tr>
</tbody>
</table>
Supplementary

Fig S1
Fig S2

A

HIF1A mRNA

<table>
<thead>
<tr>
<th></th>
<th>FA/RA</th>
<th>FA/MV-O_2</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPRT mRNA</td>
<td>1.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

B

ID1 Protein

<table>
<thead>
<tr>
<th></th>
<th>FA/RA</th>
<th>FA/MV-O_2</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>0.2</td>
<td>0.8</td>
</tr>
</tbody>
</table>

21% O_2, 40% O_2, 85% O_2

16 kDa, 43 kDa

*
Fig S3

A

B

C

D

E

Supplemental material

Fig S4

A

B

RA  O₂  MV-O₂

αSMA  αSMA  αSMA

ns  ns  *

asMA
Fig S5
Fig S6

A

B

C

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s).
Table S1. Patient characteristics preterm infants.

Data are given as median and range or number and percent of total in group respective range.
GA, gestational age; IUGR, intrauterine growth retardation; ANCS, antenatal corticosteroids; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage; ICU, intensive care unit; BPD, bronchopulmonary dysplasia. NA (not available): IUGR n=3; PDA n=7. Intrauterine growth restriction was defined as birth weight below the 10th percentile. Postnatally, diagnosis and severity of respiratory distress syndrome (RDS) were scored on anterior-posterior (a.-p.) chest radiographs according to Couchard et al (1). Chorioamnionitis was defined as inflammatory alterations of the chorionic plate (histologic examination) or signs of maternal and fetal signs of infection (2) Systemic infections were diagnosed according to Sherman et al. (3) based on one or more clinical and laboratory signs of infection. BPD was defined according to Jobe and Bancalari (4) and graded as mild (oxygen supplementation at 28 days postnatally), moderate (oxygen supplementation < 30% and/or ventilator support at 36 weeks postmenstrual age), and severe (oxygen supplementation > 30% and/or ventilator support at 36 weeks postmenstrual age).


<table>
<thead>
<tr>
<th>Status</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>28</td>
</tr>
<tr>
<td>GA (weeks)</td>
<td>28.2 (25.1-30.6)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>1031 (650-1770)</td>
</tr>
<tr>
<td>IUGR</td>
<td>2 (8%)</td>
</tr>
<tr>
<td>Gender (female/male)</td>
<td>12/16</td>
</tr>
<tr>
<td>ANCS</td>
<td>25 (89.3%)</td>
</tr>
<tr>
<td>Chorioamnionitis</td>
<td>11 (39.3%)</td>
</tr>
<tr>
<td>Early onset infection</td>
<td>7 (25.0%)</td>
</tr>
<tr>
<td>RDS≥III*</td>
<td>7 (25.0%)</td>
</tr>
<tr>
<td>Days of mechanical ventilation</td>
<td>34 (0-70)</td>
</tr>
<tr>
<td>Days of oxygen supplementation</td>
<td>22 (0-88)</td>
</tr>
<tr>
<td>PDA</td>
<td>18 (78.3%)</td>
</tr>
<tr>
<td>Postnatal steroids</td>
<td>10 (35.7%)</td>
</tr>
<tr>
<td>ROP</td>
<td>5 (17.9%)</td>
</tr>
<tr>
<td>IVH</td>
<td>2 (7.1%)</td>
</tr>
<tr>
<td>ICU days</td>
<td>64 (30-109)</td>
</tr>
<tr>
<td>BPD</td>
<td></td>
</tr>
<tr>
<td>- None</td>
<td>17 (60.7%)</td>
</tr>
<tr>
<td>- Mild</td>
<td>7 (25.0%)</td>
</tr>
<tr>
<td>- Moderate</td>
<td>3 (10.7%)</td>
</tr>
<tr>
<td>- Severe</td>
<td>1 (3.6%)</td>
</tr>
</tbody>
</table>